Sweden: XNK Therapeutics appoints Aschan as Chief Medical Officer

Stockholm-based clinical stage, cancer immunotherapy company XNK Therapeutics has named Dr Johan Aschan as Chief Medical Officer and appointed him to the management team. He takes up the position on July 1. Aschan received his MD from Karolinska Institutet (KI) in 1985 and his PhD in Clinical Immunology from KI in 1994. He has extensive…

You must be a HMI Subscriber to view this content.

Subscribe Now »